{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05206877",
            "orgStudyIdInfo": {
                "id": "63337"
            },
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Topical Insulin for Glaucoma",
            "officialTitle": "Topical Insulin for Glaucoma and Optic Neuropathies",
            "acronym": "TING1",
            "therapeuticArea": [
                "Ophthalmology"
            ],
            "study": "topical-insulin-for-glaucoma"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-04-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-06",
            "studyFirstSubmitQcDate": "2022-01-11",
            "studyFirstPostDateStruct": {
                "date": "2022-01-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-07",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Jeffrey L Goldberg",
                "investigatorTitle": "Professor of Ophthalmology",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Stanford University",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and optic disc drusen)."
        },
        "conditionsModule": {
            "conditions": [
                "Glaucoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "whoMasked": [
                        "PARTICIPANT"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Low dose topical insulin",
                    "type": "EXPERIMENTAL",
                    "description": "Group 1; N=6: 100 U/ml; 4 units of insulin per application, 1 drop done in clinic daily for 5 days",
                    "interventionNames": [
                        "Drug: Insulin, 4 units"
                    ]
                },
                {
                    "label": "High dose topical insulin",
                    "type": "EXPERIMENTAL",
                    "description": "Group 2; N=6: 500 U/ml; 20 units of insulin per application, 1 drop done in clinic daily for 5 days",
                    "interventionNames": [
                        "Drug: Insulin, 20 units"
                    ]
                },
                {
                    "label": "Longer-term topical insulin",
                    "type": "EXPERIMENTAL",
                    "description": "Group 3 randomized; N=20: 10 subjects will receive the highest tolerated dose (e.g. from group 1 or group 2), 1 drop per day at home for 1 month, full testing pre- and post-treatment, and 10 subjects will receive 1/5 of the highest tolerated dose (either the lower dose, or if needed will dilute) 1 drop per day at home for 1 month, full testing pre- and post-treatment.",
                    "interventionNames": [
                        "Drug: Insulin, 4 units",
                        "Drug: Insulin, 20 units"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Insulin, 4 units",
                    "description": "Topical insulin 100 U/ml, 1 drop per day",
                    "armGroupLabels": [
                        "Longer-term topical insulin",
                        "Low dose topical insulin"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Insulin, 20 units",
                    "description": "Topical insulin 500 U/ml, 1 drop per day",
                    "armGroupLabels": [
                        "High dose topical insulin",
                        "Longer-term topical insulin"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with Treatment-Related Adverse Events",
                    "description": "determine the safety of topical sterile human insulin in patients with optic neuropathies. AEs and SAEs will be monitored and recorded through the duration of the study.",
                    "timeFrame": "During treatment period, difference from baseline to post-treatment up to 2 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in retinal thickness measured in microns by spectral domain optical coherence tomography (sdOCT)",
                    "description": "The change in retinal thickness as measured by spectral domain optical coherence tomography (sdOCT)",
                    "timeFrame": "During treatment period, difference from baseline to post-treatment up to 2 months"
                },
                {
                    "measure": "The change in visual field as measured by mean deviation",
                    "description": "The change in visual field as measured by mean deviation on Zeiss Humphrey Visual Field testing",
                    "timeFrame": "During treatment period, difference from baseline to post-treatment up to 2 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Capable to provide informed consent\n* Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen.\n* Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.)\n* Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus\n* Inability to perform reliable visual field\n* Unable to provide informed consent\n* Unable to complete the tests and follow-ups required by the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Mariana Nunez, MD",
                    "role": "CONTACT",
                    "phone": "650-497-7846",
                    "email": "mnunez1@stanford.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jeffrey L Goldberg, MD, PhD",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Byers Eye Institute at Stanford University",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94303",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Esther Elenes",
                            "role": "CONTACT",
                            "email": "eelenes@stanford.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "No current plan to share individual participant data"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005901",
                    "term": "Glaucoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009798",
                    "term": "Ocular Hypertension"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9013",
                    "name": "Glaucoma",
                    "asFound": "Glaucoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12832",
                    "name": "Optic Nerve Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10024",
                    "name": "Hypertension",
                    "relevance": "LOW"
                },
                {
                    "id": "M12731",
                    "name": "Ocular Hypertension",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007328",
                    "term": "Insulin"
                },
                {
                    "id": "C000557859",
                    "term": "Insulin, Globin Zinc"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007004",
                    "term": "Hypoglycemic Agents"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "asFound": "Day 1",
                    "relevance": "HIGH"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "asFound": "Day 1",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17768",
                    "name": "Zinc",
                    "relevance": "LOW"
                },
                {
                    "id": "M10054",
                    "name": "Hypoglycemic Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                }
            ]
        }
    },
    "hasResults": false
}